Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Bicycle Therapeutics PLC changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 85 | 1 | 101 | +17 |
| Shares | 24.3M | 44.3K | 32.4M | +8.21M (+33.9%) |
| Value | $618.5M | $1.13M | $651.3M | +$34.0M (+5.5%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held Bicycle Therapeutics PLC at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (7)
Institutions that held Bicycle Therapeutics PLC at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Logos Global Management LP | 520,000 | $13.3M |
| Ikarian Capital, LLC | 203,037 | $5.18M |
| ExodusPoint Capital Management, LP | 111,973 | $2.86M |
| Boothbay Fund Management, LLC | 42,133 | $1.08M |
| Goldman Sachs Group Inc | 18,215 | $464.8K |
| Marshall Wace, LLP | 9,271 | $236.6K |
| Prelude Capital Management, LLC | 9,061 | $231.2K |
Not filed for Q3 2023 yet (1)
Institutions that held Bicycle Therapeutics PLC at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 44,338 | $1.13M |